ArticleScientific reports2026
Resveratrol inhibits pancreatic cancer progression via the ING5 signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with limited therapeutic options and a poor prognosis. Resveratrol (RES), a natural polyphenolic compound, has demonstrated antitumor activity in multiple cancer types; however, its underlying mechanisms in pancreatic cancer remain incompletely understood. In this study, we investigated the effects of RES on pancreatic cancer cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT), with a particular focus on the role of inhibitor of growth family member 5 (ING5). Pancreatic cancer cell lines PANC1 and SW1990 were treated with RES, and cell viability, clonogenic growth, migration, and invasion were assessed using CCK-8, colony formation, wound-healing, and Transwell assays, respectively. ING5 expression and localization were evaluated by immunofluorescence, RT-qPCR, and Western blotting, and its functional significance was further examined using siRNA-mediated knockdown. RES treatment significantly suppressed pancreatic cancer cell proliferation, migration, invasion, and EMT in vitro, accompanied by upregulation of ING5 expression and increased E-cadherin levels with concomitant reduction of N-cadherin expression. Silencing ING5 enhanced malignant cellular behaviors and partially reversed the inhibitory effects of RES on EMT-associated phenotypes and cell growth. These findings indicate that ING5 contributes to the antitumor effects of RES and functions as an important mediator in the suppression of pancreatic cancer progression. Collectively, our results suggest that RES restrains pancreatic cancer cell aggressiveness at least in part through upregulation of ING5, highlighting the RES-ING5 axis as a potential therapeutic target for pancreatic cancer intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.